German healthtech startup Brainjo has raised €2 million in fresh funding from High-Tech Gründerfonds (HTGF). The company plans to use this capital to develop a new generation of prescribable virtual reality (VR) therapy designed specifically for children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD).
Brainjo aims to combine immersive technology with clinical science to create treatments that go beyond traditional medication and behavioral therapy. This funding round marks an important step toward bringing regulated, prescription-based VR therapy into mainstream pediatric care.
A New Approach to ADHD Care
ADHD affects millions of children worldwide and often impacts attention, impulse control, and learning ability. Current treatments usually include medication, behavioral therapy, or a combination of both. While these approaches help many patients, they do not work equally well for everyone.
Brainjo focuses on a different path. The company designs VR-based therapeutic experiences that engage children in structured, interactive environments. These experiences aim to train cognitive functions such as attention control, working memory, and decision-making.
Instead of relying only on medication, Brainjo’s approach uses digital therapy as an active training tool. Children participate in targeted exercises inside virtual environments, which can adapt to their progress and needs.
Why Virtual Reality Matters
Virtual reality offers a unique advantage in therapy. It creates immersive, distraction-free environments where patients can focus on specific tasks. For children with ADHD, this controlled setting can make a significant difference.
Brainjo uses VR to simulate real-world challenges while maintaining precise control over stimuli. This allows therapists to design exercises that improve attention and reduce impulsive behavior in measurable ways.
The interactive nature of VR also increases engagement. Children often find these experiences more enjoyable than traditional therapy sessions, which can improve consistency and outcomes.
Moving Toward Prescribable Digital Therapy
One of Brainjo’s most ambitious goals involves making its VR solution prescribable by doctors. This means healthcare providers could recommend the therapy just like medication or conventional treatment.
To achieve this, Brainjo must meet strict clinical and regulatory standards. The company plans to conduct rigorous trials to demonstrate effectiveness and safety. These studies will play a crucial role in gaining approval from health authorities.
If successful, Brainjo could position itself as a leader in digital therapeutics, a growing field that combines software, medical research, and patient care.
Support from HTGF Signals Confidence
High-Tech Gründerfonds has backed Brainjo at an early stage, which reflects strong confidence in the startup’s vision. HTGF has a track record of supporting innovative deep-tech and healthcare companies in Germany.
This investment provides more than just funding. It brings strategic guidance, industry connections, and credibility. For Brainjo, this support can accelerate product development and clinical validation.
Investors increasingly show interest in digital health solutions, especially those that address unmet needs in mental health and pediatric care.
The Rise of Digital Therapeutics
Brainjo’s funding comes at a time when digital therapeutics are gaining global attention. Healthcare systems are exploring technology-driven treatments that can complement or even replace traditional methods.
Digital therapeutics offer several advantages. They can scale easily, reduce costs, and provide personalized treatment. They also allow continuous monitoring, which helps doctors track patient progress more effectively.
Companies around the world are developing software-based treatments for conditions such as anxiety, depression, and neurological disorders. Brainjo now joins this wave with a focused approach to ADHD in children.
Challenges Ahead
Despite strong potential, Brainjo faces significant challenges. Developing a clinically approved therapy requires time, resources, and rigorous testing. The company must prove that its VR solution delivers measurable improvements compared to existing treatments.
Regulatory approval represents another hurdle. Health authorities require extensive evidence before allowing prescribable digital therapies. Brainjo must navigate these processes carefully.
Adoption also depends on trust. Doctors, parents, and healthcare providers must feel confident in the effectiveness and safety of VR-based treatment.
Potential Impact on Pediatric Healthcare
If Brainjo succeeds, it could reshape how ADHD treatment works. VR therapy could become a standard option alongside medication and behavioral interventions.
This approach may reduce reliance on medication for some patients or enhance the effectiveness of existing treatments. It could also make therapy more accessible, especially in areas with limited access to specialists.
For children, the benefits could go beyond symptom management. Improved attention and cognitive skills can support better academic performance and overall development.
A Glimpse into the Future of Therapy
Brainjo’s work highlights a broader shift in healthcare. Technology continues to play a larger role in diagnosis, treatment, and patient engagement.
VR, artificial intelligence, and data analytics are transforming how medical professionals approach complex conditions. Brainjo sits at the intersection of these trends, combining immersive technology with clinical science.
As the company advances its product, it could open doors for similar innovations in other areas of mental health and neurodevelopmental disorders.
Final Thoughts
Brainjo’s €2 million funding round marks an important milestone in the evolution of ADHD treatment. The company brings a fresh perspective by integrating virtual reality into therapeutic practice.
With support from HTGF, Brainjo now has the resources to refine its technology, validate its approach, and move closer to clinical adoption. Its success could influence not only ADHD care but the entire field of digital therapeutics.
As healthcare continues to evolve, solutions like Brainjo’s VR therapy may redefine how we treat and manage complex conditions, especially in younger populations.
Also Read – Inflation vs Mutual Fund Returns (Real Data)